There is a Mary Ann Liebert at Mary Ann Liebert, Inc.

And that makes a difference!

For Immediate Release

New Study Identifies Promising Therapeutic Approach for Treating Cervical Cancer

Contact: Jennifer Gatti
914-740-2149
jgatti@liebertpub.com

Mary Ann Liebert, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com

New Rochelle, NY, August 23, 2016—A new study on ways to induce cell death in cervical cancer identifies the therapeutic potential of targeting GRIM-19, a novel tumor suppressor that binds to an oncoprotein produced by human papillomavirus (HPV), the virus that causes cells in the cervix to turn cancerous. Inhibition of GRIM-19 is associated with more advanced cervical cancer, metastasis, and a poor prognosis, whereas the presence of GRIM-19 promotes cervical cancer cell senescence by inhibiting telomerase activity, according to the study published in Journal of Interferon & Cytokine Research (JICR) from Mary Ann Liebert, Inc., publishers. The article is available free on the JICR website until September 20, 2016.

Ying Zhou and coauthors from Anhui Provincial Hospital and University of Science & Technology of China (Hefei, China) and University of Maryland School of Medicine (Baltimore, MD) describe the newly discovered mechanisms by which GRIM-19 regulates cell growth. In the article "GRIM-19 Restores Cervical Cancer Cell Senescence by Repressing hTERT Transcription," the researchers identify the binding site between GRIM-19 and the HPV oncoprotein 16E6 and explore how GRIM-19 suppresses the expression of telomere reverse transcriptase (hTERT), a component of the enzyme telomerase that can immortalize cells.

“This important paper illuminates a new mechanism of blocking cervical cancer cell growth by GRIM-19,” says Journal of Interferon & Cytokine Research Co-Editor-in-Chief Ganes C. Sen, PhD, Department of Immunology, Cleveland Clinic Foundation.

About the Journal
Journal of Interferon & Cytokine Research (JICR), led by Co-Editors-in-Chief Ganes C. Sen, PhD and Thomas A. Hamilton, PhD, Department of Immunology, Cleveland Clinic Foundation, is an authoritative peer-reviewed journal published monthly online with open access options and in print that covers all aspects of interferons and cytokines from basic science to clinical applications. Journal of Interferon & Cytokine Research is an official journal of the International Cytokine & Interferon Society. Complete tables of content and a sample issue may be viewed on the JICR website.

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Viral Immunology, AIDS Research and Human Retroviruses, and DNA and Cell Biology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

 

Mary Ann Liebert 2, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com